Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Edasalonexent with Midazolam and Deflazacort
NCT04543370Phase 1Completed
- Sponsor
- Astria Therapeutics
- Start
- Aug 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label trial of edasalonexent in Duchenne muscular dystrophy (DMD) (2 arms), sponsored by Astria Therapeutics. Primary endpoint: Area Under the Curve (AUC) of edasalonexent with midazolam and deflazacort at 12 Days. Started Aug 2020; status: completed.
02
Drugs
edasalonexent
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT04543370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04543370.